Myriad Genetics has accelerated its new test rollout under a refreshed Customer, Commercial and Clinical (CCC) strategy, unveiling two novel offerings in hereditary cancer risk and personalized pharmacogenomics during the past quarter. The myRisk® Hereditary Cancer panel now includes expanded gene coverage, driving a 25% increase in test orders from major oncology centers in Q4. Prequel®, the company’s non-invasive prenatal assessment, secured three additional national lab partnerships, positioning Myriad to capture incremental volume in women’s health. Management projects these launches will offset a portion of the headwinds from recent formulary removals in its psychiatric pharmacogenomics franchise.

In its latest quarter, Myriad reported revenue of $156.4 million, down 4% year-over-year, primarily reflecting the loss of coverage for its GeneSight test in two large payor contracts. The company recorded a net loss equivalent to ($0.19) per share, translating to a negative net margin of 48.5% and a return on equity of -7.1%. Liquidity remains robust with a current ratio of 2.33 and a quick ratio of 2.12, supported by a debt-to-equity ratio of 0.32. For the full fiscal year, management reiterated guidance in a range consistent with prior forecasts, forecasting a modest narrowing of the loss per share compared to the prior year.

Consensus sentiment on Myriad remains cautious but constructive. Since November, four major research firms have raised their price targets following the new test announcements and stabilizing revenue mix, while one firm downgraded its rating on concerns around reimbursement. The average consensus rating stands at Hold, reflecting a balance between near-term reimbursement risks and longer-term growth catalysts from expanded test volumes and strategic partnerships.

Institutional investors hold over 99% of Myriad’s shares, underscoring broad professional interest in the turnaround strategy. During the third quarter, Assenagon Asset Management increased its stake by 300%, adding roughly 1.3 million shares, while Inspire Investing more than doubled its position to over 80,000 shares. New entrants Dynamic Technology Lab and Graham Capital each initiated positions worth approximately $0.6 million. Nordea Investment Management also boosted its holdings by nearly 20%, reflecting confidence in the company’s revamped commercial approach.